-
Glimmer Of Hope: This Alzheimer Drug Failed In A Clinical Trial, But Still Shows Promise Of Halting Disease Progression
Friday, July 29, 2016 - 11:02am | 312Read More...LMTX, a drug designed to battle the effects of Alzheimer's disease, recently failed a large phase III trial, but did show signs of success when the drug was given to people who are already taking other Alzheimer medications. The drug is produced by a company called TauRX Pharmaceuticals. According...
-
Piper Jaffray On Biogen Downgrade: '6 MG Data Does Not Inspire Confidence…Even More Speculative Than Before'
Wednesday, July 22, 2015 - 11:29am | 478Read More...In a report published Wednesday, Piper Jaffray analyst Joshua Schimmer downgraded shares of Biogen Inc (NASDAQ: BIIB) to Neutral from Buy with a price target lowered to $410 from a previous $485 following the company's results for the 6mg Aducanumab arm in its P2 study for Alzheimer's....
-
The Note Moving Pharma Giants Today
Wednesday, June 17, 2015 - 4:06pm | 561Read More...Large-cap pharmaceutical companies will see revenue growth hit a peak during 2016 and 2017, followed by a wave of patent expirations in the closing three years of the current decade, an analyst said Monday. "Investors should consider protecting their portfolios against a sector de-rating" that...
-
Axovant Sciences' IPO Sparks Comment On 'Biotech Bubble'
Friday, June 12, 2015 - 10:34am | 399Read More...Axovant Sciences Ltd (NYSE: AXON) nearly doubled during its first few hours of trading Thursday, stirring comments about a biotech bubble. The company acquired its single product, a prospective treatment for Alzheimer's disease, for $5 million from GlaxoSmithKline plc (ADR) (NYSE: GSK) in December...
-
Alzheimer's Rates Falling, But Pharma's Search For A Cure Yields No Results
Thursday, July 17, 2014 - 11:12am | 691Read More...Mixed news came out this week on research into Alzheimer's. New studies suggest the rate of Alzheimer's and other forms of dementia is dropping in the United States and other developed countries. Meanwhile, Big Pharma's years-long battle to find a treatment, if not a cure,...
